
STERIS Plc Experiences Valuation Adjustment Amid Competitive Market Landscape
2025-11-03 16:10:23STERIS Plc, a midcap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, with a P/E ratio of 34 and a price-to-book value of 3.63. The company has experienced a year-to-date return of 14.66%, though it lags behind the S&P 500. Its dividend yield is 0.92%.
Read More
STERIS Plc Experiences Revision in Stock Evaluation Amid Mixed Market Signals
2025-10-07 20:54:47STERIS Plc, a midcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price fluctuate recently, currently at 240.64. Over the past year, it has experienced notable volatility. While its annual returns lag behind the S&P 500, year-to-date performance shows outperformance against the index.
Read MoreIs STERIS Plc (Ireland) technically bullish or bearish?
2025-10-06 12:11:20As of 3 October 2025, the technical trend for STERIS Plc (Ireland) has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the monthly MACD and KST also remain bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the Dow Theory shows a mildly bearish signal on the weekly chart, contrasting with a mildly bullish monthly outlook. The daily moving averages are mildly bullish. In terms of performance, STERIS has underperformed the S&P 500 over the past week and month, with returns of -2.64% and 0.02% respectively, while the S&P 500 returned 1.09% and 4.15%. However, year-to-date, STERIS has outperformed the S&P 500 with a return of 17.97% compared to 14.18%. Overall, the current technical stance is mildly bullish, but with some mixed signals indicating caution....
Read MoreIs STERIS Plc (Ireland) technically bullish or bearish?
2025-10-05 11:56:27As of 3 October 2025, the technical trend for STERIS Plc (Ireland) has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the moving averages are mildly bullish on a daily basis. However, the Dow Theory indicates a mildly bearish stance on the weekly timeframe. The Bollinger Bands reflect a mildly bullish trend for both weekly and monthly periods. In terms of performance, STERIS has underperformed the S&P 500 over the past week and month, but it has outperformed the benchmark year-to-date. Over the longer term, STERIS has lagged significantly behind the S&P 500 in 3-year and 5-year returns. Overall, the current technical stance is mildly bullish, supported by several indicators, despite some mixed signals....
Read MoreIs STERIS Plc (Ireland) technically bullish or bearish?
2025-09-20 20:07:55As of 4 September 2025, the technical trend for STERIS Plc (Ireland) has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view, including bullish MACD readings on both weekly and monthly time frames, bullish Bollinger Bands, and bullish moving averages on the daily chart. The KST shows a mildly bearish signal on the weekly but is bullish monthly, while the Dow Theory indicates a mildly bullish trend on the monthly. The On-Balance Volume is bullish for both weekly and monthly periods. In terms of performance, STERIS has a year-to-date return of 21.86%, significantly outperforming the S&P 500's 12.22%, though it lags behind the S&P over the 1-year (5.08% vs. 17.14%) and longer-term periods....
Read MoreIs STERIS Plc (Ireland) overvalued or undervalued?
2025-09-20 18:40:22As of 7 August 2025, the valuation grade for STERIS Plc (Ireland) has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 34, which is significantly higher than the industry average, and an EV to EBITDA ratio of 17.51, further supporting the notion of overvaluation. Additionally, the PEG ratio stands at 1.28, suggesting that the stock price may not be justified by its growth prospects. In comparison to its peers, STERIS Plc's P/E ratio is higher than Edwards Lifesciences Corp. at 31.17 and lower than ResMed, Inc. at 37.73, while its EV to EBITDA ratio is lower than that of Edwards Lifesciences Corp. at 26.51. The company's recent stock performance shows a year-to-date return of 21.86%, which outpaces the S&P 500's 12.22%, but over the longer term, its 3-year and 5-year returns of 29.31% and 42.40% respectively lag behind the S&P 500's 70.41% and 96.61%...
Read More





